Antengene-B (06996.HK) ：ATG-201 IND for Autoimmune Diseases Approved by China's NMPA

Newtimespace (newtimespace.com) reports that Antengene Corporation Limited (6996.HK) announced the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ATG-201, a CD19/CD3 bispecific T-cell engager antibody for the treatment of B-cell-mediated autoimmune diseases, to proceed with Phase I studies. Antengene plans to rapidly initiate and advance the Phase I study in China, while simultaneously preparing for the clinical development of ATG-201 in Australia. ATG-201 is developed based on the Company's proprietary AnTenGager® second-generation TCE platform featuring a "2+1" bivalent binding structure capable of targeting low-expression targets, integrated with steric hindrance masking technology and a proprietary CD3 sequence with rapid binding/dissociation kinetics to reduce cytokine release syndrome (CRS) risk and enhance efficacy. The Group does not guarantee that ATG-201 will ultimately be successfully developed or launched.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.